Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback

TheMotleyFool

0 0

Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback

Sanofi (NASDAQ: SNY) and GlaxoSmithKline (NYSE: GSK) hit a bit of a speed bump with their coronavirus vaccine, which didn't produce a robust immune response in clinical trial participants 50 and older. In this video from Motley Fool Live, recorded on Dec. 14, Corinne Cardina, bureau chief of healthcare and cannabis for Fool.com, and Fool.com contributor Brian Orelli discuss the data and how the vaccine differs from the currently authorized vaccines. They also talk about Sanofi and GlaxoSmithKline's backup plan to save the program.

Source Fool.com

Like: 0

SNY

Share